Background
Methods
Patients
Statistical analysis
Results
Patient characteristics
Variable | No. Patients(N = 313) | Percentage |
---|---|---|
Age at diagnosis | ||
≤ 50 | 189 | 39.6 |
> 50 | 124 | 60.4 |
Menopause status | ||
Menses | 193 | 61.7 |
Menopause | 115 | 36.7 |
Unknown | 5 | 1.6 |
Biopsy | ||
Mass resection | 27 | 8.6 |
Core needle | 229 | 73.2 |
Fine needle | 1 | 0.3 |
Unknown | 56 | 17.9 |
Tumor size | ||
≤ 5 cm | 174 | 55.6 |
> 5 cm | 120 | 38.3 |
Unknown | 19 | 6.1 |
Lymph node involvement | ||
N0 | 28 | 8.9 |
N1 | 44 | 14.1 |
N2 | 71 | 22.7 |
N3 | 129 | 41.2 |
Unknown | 41 | 13.1 |
Hormone receptor status | ||
+ | 212 | 67.7 |
- | 94 | 30.0 |
Unknown | 7 | 2.2 |
HER2 receptor status | ||
Amplified | 132 | 42.2 |
No-amplified | 161 | 51.4 |
Not known or equivocal(2+) | 20 | 6.4 |
Molecular subtype | ||
Luminal A | 55 | 17.6 |
Luminal B | 141 | 45.0 |
HER2 | 56 | 17.9 |
Triple negative | 33 | 10.5 |
Unknown* | 28 | 8.9 |
Surgery | ||
Yes | 188 | 60.1 |
No | 125 | 39.9 |
Type of surgery | ||
Modified radical mastectomy | 181 | 96.3 |
Lumpectomy | 3 | 1 |
Simple mastectomy | 4 | 1.3 |
Margin status | ||
Negative | 184 | 97.9 |
Positive | 4 | 2.1 |
Endocrine therapy$ | ||
Yes | 123 | 39.3 |
No | 190 | 60.7 |
Anti-HER2 therapy$ | ||
Yes | 71 | 22.7 |
No | 239 | 76.4 |
Unknown | 3 | 1 |
Chemotherapy(first line regimen)$ | ||
CAF/CEF | 9 | 2.9 |
Taxane based/taxane +anthracyline | 241 | 77.0 |
Platinum based | 17 | 5.4 |
Others | 20 | 6.4 |
Unknown | 26 | 8.3 |
Bisphosphonate | ||
Yes | 92 | 29.4 |
No | 221 | 70.6 |
OFS* | ||
Yes | 58 | 18.5 |
No | 255 | 81.5 |
Radiotherapy | ||
Yes | 99 | 31.6 |
No | 184 | 58.8 |
Unknown | 30 | 9.6 |
Viscera metastasis | ||
Yes | 167 | 53.4 |
No | 146 | 46.6 |
Bone metastasis | ||
Yes | 171 | 54.6 |
No | 142 | 45.4 |
CNS metastasis* | ||
Yes | 11 | 3.5 |
No | 302 | 96.5 |
Soft tissue metastasis | ||
Yes | 139 | 44.4 |
No | 174 | 55.6 |
No. of metastasis sites | ||
≤ 3 | 288 | 92.0 |
> 3 | 25 | 8.0 |
Overall survival(months) | ||
Median | 62 | – |
95% Confidence interval | 45.79–78.21 | – |
Variable | Nonsurgical(N = 125) | Surgical(N = 188) | p value& |
---|---|---|---|
Age | |||
≤ 50 | 83(43.7%) | 1107(56.3%) | 0.092 |
> 50 | 42(34.1%) | 781(65.9%) | |
Menopause status | |||
Menses | 72(36.8%) | 1122(63.2%) | 0.144 |
Menopause | 51(45.2%) | 663(54.8%) | |
Tumor size | |||
≤ 5 cm | 63(36.2%) | 1111(63.8%) |
0.018
|
> 5 cm | 60(50.0%) | 560(50.0%) | |
Lymph node involvement | |||
N0 | 5(17.9%) | 223(82.1%) |
0.018#
|
N1 | 21(47.7%) | 23(52.3%) | |
N2 | 31(43.7%) | 340(56.3%) | |
N3 | 65(50.4%) | 664(49.6%) | |
HER-2 receptor status | |||
Amplified | 49(37.1%) | 783(62.9%) | 0.657£ |
No-amplified | 67(41.6%) | 994(58.4%) | |
Not known or equivocal(2+) | 49(45.0%) | 511(55.0) | |
Hormone receptor status | |||
H+ | 81 (38.2%) | 1131 (61.8%) | 0.588 |
H- | 39(41.5%) | 555(58.5%) | |
Molecular subtype | |||
Luminal A | 19(34.5%) | 36(65.5%) | 0.194 |
Luminal B | 54(38.3%) | 887(61.7%) | |
HER2 | 23(41.1%) | 333 (58.9%) | |
Triple negative | 12 (36.4%) | 21 (63.6%) | |
Unknown | 117 (60.7%) | 911 (39.3%) | |
Viscera metastasis | |||
Yes | 80 (47.9) | 887 (52.1) |
0.002
|
No | 45 (30.8%) | 9101 (69.2%) | |
Bone metastasis | |||
Yes | 75(43.9%) | 996(56.1%) | 0.120 |
No | 50(35.2%) | 892(64.8%) | |
CNS metastasis* | |||
Yes | 6(54.5%) | 5(45.5%) | 0.314 |
No | 119(39.4%) | 1183(60.6%) | |
Soft tissue metastasis | |||
Yes | 58(42.3%) | 779(57.7%) | 0.297 |
No | 67(38.1%) | 1109(61.9%) | |
No. of metastatic sites | |||
≤ 3 | 107(37.2%) | 1181(62.8%) |
< 0.001
|
> 3 | 18(72%) | 67(28%) | |
Endocrine therapy$ | |||
Yes | 35(28.5%) | 888(71.5%) |
0.001
|
No | 90(47.4%) | 9100(52.6%) | |
Anti-HER2 therapy$ | |||
Yes | 24(33.8%) | 447(66.2%) | 0.055£ |
No | 98(41.0%) | 1141(59.0%) | |
Unknown | 3(100%) | 0 | |
OFS* | |||
Yes | 12(20.7%) | 446(79.3%) |
0.001
|
No | 113(44.3%) | 1142(55.7%) | |
Radiotherapy | |||
Yes | 18(18.2%) | 781(81.8%) |
< 0.001
|
No | 81(44.0%) | 1103(56.0%) | |
Unknown | 26(86.7%) | 4(13.3%) |
Univariable and multivariable analysis
Characteristic | Univariable HR*(95%CI) | P | Multivariable HR*(95%CI) | P |
---|---|---|---|---|
Surgery | ||||
Yes vs No | 0.56(0.382-0.820) |
0.003
| 0.53(0.36-0.78) |
0.001
|
Viscera metastasis | ||||
Yes vs no | 1.73 (1.18-2.54) |
0.005
| ||
Bone metastasis | ||||
Yes vs no | 0.91 (0.62-1.32) | 0.610 | ||
CNS metastasis | ||||
Yes vs no | 1.40 (0.44-4.43) | 0.566 | ||
Soft tissue metastasis | ||||
Yes vs no | 0.99 (0.68-1.46) | 0.977 | ||
Age | ||||
≤50 vs >50 | 0.65 (0.44-0.95) |
0.026
| ||
Menopause status | ||||
Menopause vs menses | 1.21 (0.82-1.77) | 0.344 | ||
Biopsy | ||||
mass resection | 1§ | 0.753 | ||
core needle | 1.32 (0.64-2.73) | 0.457 | ||
fine needle | 1.43 (0.18-11.59) | 0.736 | ||
Histology | ||||
ductal | 1§ | 0.824 | ||
lobular | 0.66 (0.16-2.69) | 0.563 | ||
others | 1.11 (0.41-3.05) | 0.835 | ||
Tumor size | ||||
>5 cm vs ≤5 cm | 1.00 (0.67-1.49) | 0.981 | ||
Lymph node involvement | ||||
N0 | 1§ | 0.259 | ||
N1 | 2.48 (1.00-6.11) | 0.049 | ||
N2 | 1.95 (0.80-4.74) | 0.142 | ||
N3 | 2.14 (0.91-5.05) | 0.081 | ||
HER2 receptor status | ||||
Amplified | 1§ | 0.557 | ||
No-amplified | 0.81 (0.55-1.21) | 0.304 | ||
Not known or equivocal(2+) | 0.77 (0.31-1.93) | 0.574 | ||
Hormone receptor status | ||||
+ vs - | 0.49 (0.321-0.7233) |
<0.001
| 0.57 (0.36-0.89) |
0.013
|
No. of metastasis sites | ||||
>3 vs ≤3 | 1.751 (0.881-3.477) | 0.11 | ||
Endocrine therapy$ | ||||
Yes vs no | 0.45 (0.30-0.68) |
<0.001
| 0.55 (0.35-0.86) |
0.009
|
Anti-HER2 therapy$ | ||||
No | 1§ | 0.11 | ||
Yes | 0.54 (0.325-1.008) | 0.035 | ||
Unknown | 0.00 (0.00-5.357E+159) | 0.959 | ||
Radiotherapy | ||||
No | 1§ |
0.029
| ||
Yes | 0.61 (0.40-0.94) | 0.025 | ||
Unknown | 1.35 (0.71-2.57) | 0.357 |